Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis, Hereditary Hemorrhagic Telangiectasia
About this trial
This is an interventional treatment trial for Epistaxis focused on measuring Epistaxis, Hereditary Hemorrhagic Telangiectasia, HHT, Sclerotherapy, Epistaxis (nosebleeds) due to Hereditary Hemorrhagic Telangiectasia
Eligibility Criteria
Inclusion Criteria:
- a clinical diagnosis of HHT based on the Curacoa Criteria
- age 18 and older
- cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires
Exclusion Criteria:
- previous sclerotherapy with Sodium Tetradecyl Sulfate
Sites / Locations
- University of Minnesota Otolaryngology Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Standard Treatment then Sclerotherapy Intervention
Sclerotherapy Intervention then Standard Treatment'
The standard treatment group will continue their pre-study "standard treatment" methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks
This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks